Mifepristone vs Misoprostol
NCT06502158
Recruiting
The Investigator team hypothesizes that in a randomized trial comparing mifepristone-alone or misoprostol-alone for cervical preparation for procedural abortions at 12 to 16 weeks in hospital-based care, the proportion of patients who achieve successful cervical dilation will be different between the study groups.
Gender:
FEMALE
Ages:
Between 18 years and 45 years
Trial Updated:
08/07/2025
Locations: Montefiore Medical Center, Bronx, New York
Conditions: Cervical Preparation
Register for Updates
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
NCT06541704
Recruiting
This study is researching experimental (study) drugs called pozelimab and cemdisiran. The study is focused on participants who have Geographic Atrophy (GA) caused by Age-related Macular Degeneration (AMD). Geographic atrophy is a medical term that refers to later-stage cases of AMD which is an eye condition affecting central vision (what one sees straight ahead). The purpose of this study is to evaluate the progression rate of Geographic Atrophy in eyes of patients treated with cemdisiran alone... Read More
Gender:
ALL
Ages:
Between 50 years and 85 years
Trial Updated:
08/07/2025
Locations: Barnet Dulaney Perkins Eye Center, Phoenix, Arizona +91 locations
Conditions: Age-related Macular Degeneration (AMD), Geographic Atrophy (GA)
Register for Updates
A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome)
NCT06616636
Recruiting
A non-randomized phase Ib study of PC14586 (PMV therapeutics) in patients diagnosed with TP53Y220C-mutant myeloid malignancies, including AML and MDS.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/07/2025
Locations: The University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Myelodysplastic Syndrome, Acute Myeloid Leukemia
Register for Updates
An Integrative Multi-Omic Characterization of Head and Neck Carcinogenesis, Progression and Recurrence
NCT06420219
Recruiting
This study evaluates the cell and biomarkers associated with the aggressive behavior of cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/07/2025
Locations: USC / Norris Comprehensive Cancer Center, Los Angeles, California
Conditions: Head and Neck Carcinoma
Register for Updates
Social Facilitation of Alcohol Effects and Alcohol Misuse in Young Adults
NCT06627803
Recruiting
The purpose of this study is to understand social contexts and alcohol use. We hope to learn how being around peers affects alcohol consumption in young adults. About 200 young adults who drink alcohol frequently will take part in the study. This research is being funded by the National Institute on Alcohol Abuse and Alcoholism (NIAAA). Participation involves one in-person screening session with a same-sex platonic friend. Then participants will complete four in-person laboratory sessions where... Read More
Gender:
ALL
Ages:
Between 21 years and 28 years
Trial Updated:
08/07/2025
Locations: University of Southern California, Los Angeles, California
Conditions: Alcohol Consumption, Alcohol Abuse/Dependence
Register for Updates
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
NCT06617325
Recruiting
The purpose of this study is to evaluate the ability of dapirolizumab pegol (DZP) as an add-on treatment to standard of care (SOC) medication to achieve clinically relevant long term improvement of moderate to severe disease activity.
Gender:
ALL
Ages:
16 years and above
Trial Updated:
08/07/2025
Locations: Sl0044 50058, Avondale, Arizona +158 locations
Conditions: Systemic Lupus Erythematosus
Register for Updates
Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.
NCT06590857
Recruiting
Phase 1b/2 open-label trial of 225Ac-DOTATATE (RYZ101) in subjects with ER+, HER2-negative unresectable or metastatic breast cancer expressing SSTRs.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/07/2025
Locations: Research Facility, Phoenix, Arizona +22 locations
Conditions: Metastatic Breast Cancer, HER2-negative Breast Cancer, ER+ Breast Cancer, Advanced Breast Cancer
Register for Updates
A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)
NCT06615050
Recruiting
The purpose of this study is to assess Tacrolimus/Methotrexate/Ruxolitinib versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/07/2025
Locations: Stanford Cancer Center, Palo Alto, California +19 locations
Conditions: Graft-versus-host Disease (GVHD)
Register for Updates
Dose-Response to Resistance Exercise on Cardiovascular Health
NCT06619444
Recruiting
A large body of evidence indicates numerous health benefits of physical activity, including prevention of cardiovascular disease (CVD), the leading cause of death in the US. This evidence has led to US Physical Activity Guidelines that recommend ≥150 min/week of moderate or ≥75 min/week of vigorous aerobic exercise (AE), plus resistance exercise (RE; such as weight lifting) on ≥2 days/week. To date, current research has mostly focused on AE, and we know a great deal about the dose-response relat... Read More
Gender:
ALL
Ages:
40 years and above
Trial Updated:
08/07/2025
Locations: Physical Activity Research Center (PARC), Pittsburgh, Pennsylvania
Conditions: Cardiovascular Risk
Register for Updates
A Study to Test the Safety and Effects of Inhaled GDC-6988 in Participants With Muco-Obstructive Disease
NCT06603246
Recruiting
This study evaluates the safety, tolerability, and activity of inhaled GDC-6988 in participants with muco-obstructive disease.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/07/2025
Locations: Accel Research Site - Achieve - Birmingham - ERN - PPDS, Vestavia Hills, Alabama +2 locations
Conditions: Non Cystic Fibrosis Bronchiectasis, Chronic Obstructive Pulmonary Disease
Register for Updates
Syncing Screening and Services for Suicide Prevention Across Health and Justice Systems
NCT06506344
Recruiting
This study aims to harmonize jail release record data with electronic health record data in order to connect patients to an evidence-based suicide prevention and clinical care pathway upon jail release.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/07/2025
Locations: Henry Ford Health, Detroit, Michigan +1 locations
Conditions: Suicide Prevention
Register for Updates
A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations
NCT06644768
Recruiting
This study will compare Valemetostat Tosylate Plus Pembrolizumab vs Pembrolizumab Alone in First-line NSCLC Without Actionable Genomic Alterations
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/07/2025
Locations: University of California San Diego (Ucsd)-Moores Cancer Center, La Jolla, California +44 locations
Conditions: Non-small Cell Lung Cancer, Lung Cancer
Register for Updates